Merck & CompanyvsVera Therapeutics

MRK and VERA stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

VERA

Vera Therapeutics, Inc.

$25.45

Value $1.8B

-4.86%
VERA's page

Merck & Company (MRK) has a market value of $331B and Vera Therapeutics (VERA) $1.8B. Over the last year, with dividends, MRK moved +44.8% and VERA -10.9%. Dividend yield: MRK 2.54%, VERA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    VERA$1.8B

    MRK is 180 times VERA

  • Revenue, 12 months

    MRK$67.4B

    VERA–

  • Net income, 12 months

    MRK$2.5B

    VERA-$415M

  • Operating margin

    MRK–

    VERA–

  • ROIC

    MRK3.9%

    VERA-36.7%

    40.6 points apart

  • P/E

    MRK134.8

    VERA–

  • Dividend yield

    MRK2.5%

    VERA0.0%

    2.5 points apart

  • 5-year return

    MRK+93.0%

    VERA-18.4%

    111.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+93.0%

VERA-18.4%

10020020222023202420252026
Returns by period
PeriodMRKWith dividendsVERAWith dividends
1 year since November 19, 2025+44.8%Price +40.7%-10.9%Price -10.9%
3 years since November 20, 2023+42.7%+12.6% a yearPrice +30.2%+88.5%+23.5% a yearPrice +88.5%
5 years since November 19, 2021+93.0%+14.1% a yearPrice +65.7%-18.4%-4.0% a yearPrice -18.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyVERAVera Therapeutics

Valuation

MRKVERA
Valuation
Price$133.72$25.45
Market value$331B$1.8B
Enterprise value (EV)$375B$1.5B
P/E134.8–
P/E, 5-year median14.8–
P/B7.45.5
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKVERA
Results and growth
Revenue, 12 months$67.4B–
Net income, 12 months$2.5B-$415M
Free cash flow, 12 months$14.7B-$376M
Earnings per share, 12 months$0.98-$5.90
Revenue growth, year on year1.3%–
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKVERA
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%-36.7%
ROE5.2%-92.5%

Balance sheet

MRKVERA
Balance sheet
Cash$9.7B$384M
Total debt$53.8B$75M
Net debt / EBITDA5.7–
Interest cover2.4×-42.4×

Dividends and buybacks

MRKVERA
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or VERA

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Vera Therapeutics?

By market value, Merck & Company ($331B) is about 179.7 times Vera Therapeutics ($1.8B), at today's prices.

How did MRK and VERA stock do over the last 5 years?

Since November 19, 2021, MRK's price moved +65.7% and VERA's -18.4%. With dividends: MRK +93.0% (+14.1% a year), VERA -18.4% (-4.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or VERA?

The dividend yield at today's price is 2.54% for Merck & Company and none for Vera Therapeutics. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or Vera Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.